<DOC>
	<DOCNO>NCT03045406</DOCNO>
	<brief_summary>Apixaban treatment venous thromboembolism patient cancer : prospective randomize open blind end-point ( PROBE ) study</brief_summary>
	<brief_title>Apixaban Treatment Venous Thromboembolism Patients With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Consecutive patient newly diagnose , objectively confirm : symptomatic unsuspected , proximal lowerlimb DVT symptomatic PE unsuspected PE segmental proximal pulmonary artery ; Any type cancer ( basalcell squamouscell carcinoma skin , primary brain tumor intracerebral metastasis acute leukemia ) ; Signed date informed consent patient , available start specific trial procedure . age &lt; 18 year ; ECOG Performance Status III IV ; life expectancy le 6 month ; Related anticoagulant treatment : administration therapeutic dos LMWH , fondaparinux , unfractionated heparin ( UFH ) 72 hour randomization ; 3 dos vitamin K antagonist randomization ; thrombectomy , vena cava filter insertion , thrombolysis use manage index episode ; indication anticoagulant treatment disease index VTE episode ; Related bleeding risk : thienopyridine therapy ( clopidogrel , prasugrel , ticagrelor ) aspirin 165 mg daily dual antiplatelet therapy ; active bleeding high risk bleed contraindicate anticoagulant treatment ; recent ( last 1 month prior randomization ) brain , spinal ophthalmic surgery hemoglobin level lower 8 g/dL ( 5.0 mmol/L ) platelet count &lt; 75x10^9/L history heparin induce thrombocytopenia ; creatinine clearance &lt; 30 ml /min base Cockcroft Gault equation ; acute hepatitis , chronic active hepatitis , liver cirrhosis ; alanine aminotransferase level 3 time and/or bilirubin level 2 time high upper limit normal range ; uncontrolled hypertension ( systolic BP &gt; 180 mmHg diastolic BP &gt; 100 mmHg despite antihypertensive treatment ) ; concomitant use strong inhibitor inducer cytochrome P450 3A4 PGlycoprotein ; Standard criterion : bacterial endocarditis ; hypersensitivity active substance excipients study drug ; patient participation pharmaco therapeutic program experimental therapy know effect coagulation system ; childbearing potential without proper contraceptive measure , pregnancy , breast feeding ; condition judge Investigator would place subject increase risk harm he/she participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>